Ohtahara syndrome is a severe early-onset epileptic encephalopathy in which achieving adequate seizure control is the central clinical challenge. The primary therapeutic aim is suppression of seizures.
This protocol addresses first-line pharmacological management of Ohtahara syndrome, where seizure control remains the defining treatment goal.
Management centres on antiepileptic drug therapy. Available evidence is largely anecdotal, and effectiveness in controlling seizures is limited. The full structured regimen — including which agents and in what context — is detailed in the protocol.
Control of seizures.
DOI: 10.1016/j.pediatrneurol.2012.06.002
Only anecdotal evidence supports the use of specific antiepileptic drugs in these conditions.
Phenobarbital, valproate, pyridoxine, zonisamide, and benzodiazepines have all demonstrated limited effectiveness in seizure control in Ohtahara syndrome.
View source ↗